Paper11675350
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
Bellosillo B and 7 others. Blood, 2001. Cited by 166 papers, by iCite.
Cite this record
ConductScience Library. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Papers, record 11675350. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11675350
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| B-Lymphocytes | Major topic |
| Caspases | Major topic |
| Cell Death | Major topic |
| Complement System Proteins | Major topic |
| Lymphoproliferative Disorders | Major topic |
| Reactive Oxygen Species | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Antibodies, Monoclonal, Murine-Derived | |
| Antigens, CD20 | |
| Antineoplastic Agents | |
| CD55 Antigens | |
| CD59 Antigens | |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Rituximab |
Source PubMed
Cited by67
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 166 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42426484 | The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis. | Eur J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42426484 | PubMed |
| 41909695 | Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification. | Front Immunol | 2026 | https://conductscience.org/library/papers/41909695 | PubMed |
| 41469420 | Novel anti-ITGA4 monoclonal antibody induces cell death via large pore formation in NK/T-cell lymphoma cells. | Sci Rep | 2025 | https://conductscience.org/library/papers/41469420 | PubMed |
| 40576254 | Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases. | Ther Drug Monit | 2025 | https://conductscience.org/library/papers/40576254 | PubMed |
| 38671922 | Potential New Therapies "ROS-Based" in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis. | Antioxidants (Basel) | 2024 | https://conductscience.org/library/papers/38671922 | PubMed |
| 36968995 | The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives. | Front Oncol | 2023 | https://conductscience.org/library/papers/36968995 | PubMed |
| 35147819 | Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. | Dig Dis Sci | 2022 | https://conductscience.org/library/papers/35147819 | PubMed |
| 33198328 | Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies. | Antioxidants (Basel) | 2020 | https://conductscience.org/library/papers/33198328 | PubMed |
| 32255851 | Cytotoxic Effect of Prodigiosin, Natural Red Pigment, Isolated from Serratia marcescens UFPEDA 398. | Indian J Microbiol | 2020 | https://conductscience.org/library/papers/32255851 | PubMed |
| 30962539 | Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model. | Sci Rep | 2019 | https://conductscience.org/library/papers/30962539 | PubMed |
| 30655772 | Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells. | Oncol Lett | 2019 | https://conductscience.org/library/papers/30655772 | PubMed |
| 30504310 | Novel immunotherapy approaches to follicular lymphoma. | Hematology Am Soc Hematol Educ Program | 2018 | https://conductscience.org/library/papers/30504310 | PubMed |
| 30308958 | Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30308958 | PubMed |
| 30096012 | Anti-CD20 monoclonal antibodies: reviewing a revolution. | Hum Vaccin Immunother | 2018 | https://conductscience.org/library/papers/30096012 | PubMed |
| 29770165 | Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies. | Oxid Med Cell Longev | 2018 | https://conductscience.org/library/papers/29770165 | PubMed |
| 28698765 | Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy. | Oxid Med Cell Longev | 2017 | https://conductscience.org/library/papers/28698765 | PubMed |
| 28213834 | Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular Imaging. | Mol Imaging Biol | 2017 | https://conductscience.org/library/papers/28213834 | PubMed |
| 27069950 | Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic. | Mol Ther Methods Clin Dev | 2016 | https://conductscience.org/library/papers/27069950 | PubMed |
| 26283682 | Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26283682 | PubMed |
| 25859860 | Role of complement and complement regulatory proteins in the complications of diabetes. | Endocr Rev | 2015 | https://conductscience.org/library/papers/25859860 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| CD59 | 966 | PubTator's text mining | https://conductscience.org/library/genes/966 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11675350
GET https://conductscience.org/api/papers/v1/11675350/cited_by?page=2